any reason why they are looking at NAFLD and not NASH in the 1b? Does the FDA want some safety data in NAFLD before looking at more advanced diseased pts? The ultimate target population for the drug is NASH after all
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.